PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth below 50% of Healthcare median of 1.84%. Jim Chanos would suspect fundamental margin deterioration.
56.85%
EBIT growth of 56.85% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
54.90%
Operating income growth exceeding 1.5x Healthcare median of 4.88%. Joel Greenblatt would see if unique processes drive exceptional profitability.
56.85%
Net income growth of 56.85% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
56.86%
EPS growth of 56.86% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
56.86%
Diluted EPS growth of 56.86% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Healthcare median is 0.40%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Healthcare median is 0.31%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth of 28.81% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
28.81%
FCF growth of 28.81% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
95.99%
OCF/share CAGR of 95.99% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
56.40%
OCF/share CAGR of 56.40% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
-114.69%
Negative 3Y OCF/share CAGR while Healthcare median is 9.02%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
96.39%
Net income/share CAGR exceeding 1.5x Healthcare median of 30.98% over a decade. Joel Greenblatt might see a standout compounder of earnings.
45.76%
5Y net income/share CAGR > 1.5x Healthcare median of 16.68%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
32.63%
3Y net income/share CAGR > 1.5x Healthcare median of 21.37%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
-96.80%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-86.34%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-81.50%
Negative 3Y equity/share growth while Healthcare median is -32.77%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-26.00%
Negative BV/share change while Healthcare median is -1.25%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-9.98%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-36.64%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-70.64%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.